Shopping Cart
Urology · regenerative procedures · evidence assessment
PRP and erectile dysfunction
This article provides a factual overview of causes, established treatment approaches, clinical studies, guideline positions and technical aspects of PRP preparation.
- Diagnostics
- Guidelines
- Placebo-controlled studies
- Safety
- PRP preparation
Guideline statusIn the urological guidelines reviewed, PRP is classified as experimental or not yet sufficiently supported by evidence.
Study findingsRandomised studies report differing results compared with placebo.
ProtocolsPreparation, dosage and treatment intervals differ between the published studies.
Erectile dysfunction can have many different causes. In addition to vascular disease, diabetes and hormonal changes, neurological, medication-related and psychological factors may be involved. For several years, researchers have been investigating whether platelet-rich plasma, or PRP, could improve erectile function.
The published results are not consistent. This article presents the available data, their methodological differences and the positions of urological guidelines without deriving an individual recommendation for or against a procedure.
What is erectile dysfunction?
Erectile dysfunction, abbreviated ED, is present when an erection sufficient for satisfactory sexual activity cannot be achieved or maintained over a prolonged period.
Occasional erection problems do not automatically indicate a medical condition. Recurrent or persistent symptoms should nevertheless be assessed by a doctor. Erectile dysfunction can affect quality of life and relationships, and may also point to previously unrecognised health problems.
More than a sexual symptomNew-onset erectile dysfunction may be associated with vascular and metabolic disease. Medical assessment should therefore not be limited to erectile function alone.
What can cause erectile dysfunction?
An erection requires coordinated interaction between blood vessels, nerves, hormones, erectile tissue and psychological arousal. Disturbances in one or more of these areas can impair erectile function.
Vascular and metabolic factorsHigh blood pressure, diabetes, lipid disorders, excess weight, smoking and physical inactivity.
Hormones and medicinesTestosterone deficiency, other hormonal disorders and side effects of certain medicines.
Nerves and medical proceduresNeurological conditions as well as surgery or radiotherapy in the pelvic region.
Psychological and anatomical factorsDepression, anxiety, stress, relationship conflicts and changes such as Peyronie’s disease.
In many cases, there is no single cause. Organic and psychological factors can reinforce one another.
Why medical assessment matters
Current guidelines also regard erectile dysfunction as a possible marker of increased cardiovascular risk. Particularly in men with high blood pressure, diabetes, elevated blood lipids, excess weight or nicotine use, assessment should not focus only on the sexual symptom.
Basic diagnostic assessment generally includes:
- medical and sexual history,
- physical examination,
- blood pressure and, where appropriate, weight and waist circumference,
- blood glucose or HbA1c,
- blood lipid levels,
- morning total testosterone,
- additional hormonal or vascular examinations where required.
Questionnaires such as the International Index of Erectile Function, or IIEF, can help document the severity of symptoms and changes over time.
Which treatments are established?
Treatment is based on the cause, severity, comorbidities and the patient’s preferences. Modifiable risk factors should generally be addressed as part of care.
Exercise, smoking cessation, weight reduction and better control of blood pressure, blood glucose and blood lipids.
For example sildenafil or tadalafil, provided there are no medical contraindications.
Vacuum erection devices, alprostadil or intracavernosal injections of erection-inducing medicines.
Sexual medicine support and, in selected cases, implantation of a penile prosthesis.
What is PRP?
PRP stands for platelet-rich plasma. It is obtained from the patient’s own blood. Centrifugation separates the blood components and prepares a plasma fraction with an increased platelet concentration.
Platelets contain various signalling proteins and growth factors. Preclinical models investigate possible effects on new blood vessel formation, tissue responses and repair processes. This led to the hypothesis that intracavernosally injected PRP might have an effect in certain forms of erectile dysfunction.
Assessment of the biological rationale Preclinical research examines possible effects on blood vessels and tissue responses. Whether and to what extent these observations translate into clinical effects is being studied in human trials. Conventionally prepared PRP is not a stem-cell therapy.
How has PRP been used in studies?
In the studies conducted so far, PRP was injected directly into the corpora cavernosa. However, the studies used different preparation systems, blood volumes, platelet concentrations, activation methods, injection volumes and treatment intervals.
Two or three sessions several weeks apart were often used. This does not establish a generally applicable treatment protocol. Results obtained with one PRP system cannot automatically be transferred to another tube, centrifuge or preparation method.
Simplified procedure in clinical studies
The specific procedure differed between studies. The diagram shows only the general steps.
Step 1Blood collection
Autologous blood is collected in a tube intended for the respective system.
Step 2Preparation
Centrifugation according to a defined, product-specific protocol.
Step 3Intracavernosal administration
Injection according to the study protocol by appropriately qualified medical professionals.
What do the clinical studies show?
The study findings are inconsistent. One small randomised, placebo-controlled trial involving 60 men reported better IIEF-EF scores after two PRP injections than in the placebo group. Other placebo-controlled studies found no relevant difference.
Example of a positive placebo-controlled studySmall study in mild to moderate erectile dysfunction
60Participants
2PRP injections
69%clinically relevant improvement in the PRP group
27%clinically relevant improvement with placebo
The study was small, conducted at a single centre and used a specific preparation system. Its results therefore cannot automatically be generalised.
What do pooled analyses show?
Earlier meta-analyses partly concluded that erectile function scores might improve after PRP compared with baseline or placebo. However, the strength of the evidence was limited by small patient numbers, inconsistent study designs and differing PRP protocols.
More recent analyses of randomised, placebo-controlled studies found no consistent advantage of platelet-based therapies over placebo in pooled IIEF scores. Individual endpoints were more favourable, but were based on only part of the available studies.
Overall assessment of the evidence
An interesting area of research, but not yet a robust basis for a regular standard treatment.
very uncertainhighly reliable
How do guidelines assess PRP?
The European guideline reports that slight improvements were observed in individual studies involving patients with organic erectile dysfunction. At the same time, it considers the evidence insufficient for a recommendation in routine clinical practice.
The American Urological Association describes PRP as an experimental procedure in its guideline. Both documents reflect the literature reviewed and the time at which they were published.
Guideline assessment The guidelines reviewed do not currently provide a regular recommendation for routine clinical practice. This statement describes the status of the guidelines and does not replace an individual medical assessment.
What safety data are available?
Most published randomised studies did not report serious adverse events. However, they involved relatively small groups and generally limited follow-up periods.
Reviews mainly mention mild local reactions; haematomas and plaque formation were reported in isolated cases. Safety data also depend on injection technique, preparation, patient selection and follow-up.
The available data do not support this general statement. Procedure-related and injection-related risks also exist with autologous material.
The clinical data reviewed do not demonstrate reliable penile enlargement.
Preclinical hypotheses and clinical evidence of efficacy must be distinguished; a confirmed effect in humans cannot be derived from them.
The studies use different follow-up periods and do not provide a generally applicable duration of effect.
Technical aspects of PRP preparation
The composition of a PRP fraction is influenced by the preparation system used. When transferring a study protocol, relevant factors include relative centrifugal force, rotor radius, run time, tube system and other process parameters.
Depending on the system, suitable PRP tubes and a compatible centrifuge are used in a professional workflow. Vi PRP-PRO PRP tubes and the Hettich EBA 200 MD are mentioned as technical examples from the product range.
PRP tubes
Vi PRP-PRO
According to the product information, the tube contains borosilicate glass, sodium citrate and a thixotropic separation gel, with a preparation protocol of 1,200 × g for seven minutes.
Technical product dataCentrifuge
Hettich EBA 200 MD
The manufacturer specifies an integrated eight-place fixed-angle rotor, a maximum capacity of 8 × 10 ml, up to 6,000 rpm and 3,461 × g.
Technical device dataTechnical assessment The product data mentioned relate to technical PRP preparation. Their inclusion does not support any statement regarding suitability, efficacy or approval for a specific urological application.
Which points are relevant to professional assessment?
The clinical studies differ in patient selection, cause and severity of erectile dysfunction, PRP preparation, dosage, number of sessions and follow-up. These differences make direct comparison of the results difficult.
The following points are particularly relevant when assessing the published data:
- inclusion and exclusion criteria of the respective study,
- cause and severity of erectile dysfunction,
- PRP system used and documented preparation parameters,
- control group, endpoints and duration of follow-up,
- type and frequency of documented adverse events.
Summary of the evidence
PRP in erectile dysfunction is the subject of clinical research. Some studies report improvements, while others show no relevant differences compared with placebo. Pooled analyses therefore do not provide a consistent assessment of efficacy.
Questions remain regarding the appropriate patient group, standardisation of PRP preparation, dosage, number of applications and duration of possible effects. Future larger and methodologically comparable studies may clarify these points.
Frequently asked questions
How do urological guidelines classify PRP for erectile dysfunction?
The guidelines reviewed describe PRP as experimental or as not yet sufficiently supported for a regular recommendation in routine clinical practice.
Has PRP been compared directly with PDE5 inhibitors such as sildenafil?
The studies covered in this article mainly compare PRP with placebo or assess changes from baseline. They do not support a general comparison suggesting replacement of PDE5 inhibitors.
What adverse events have been described?
The small studies mainly documented mild local reactions. Haematomas and plaque formation were reported in isolated cases; long-term data remain limited.
Is there a standardised PRP protocol for erectile dysfunction?
No. Blood volume, tube system, centrifugation, platelet concentration, activation, injection volume and treatment intervals differ between studies.
Why are PRP tubes and the Hettich EBA 200 MD mentioned?
They are cited as examples of technical components used in a professional PRP preparation process. This does not imply any statement about a specific urological application.
Sources and further information
- European Association of Urology: Management of Erectile Dysfunction
- American Urological Association: Erectile Dysfunction Guideline
- Poulios E et al.: Platelet-Rich Plasma Intracavernosal Injections for the Treatment of Erectile Dysfunction
- PubMed: Systematic review and meta-analysis on PRP for erectile dysfunction
- PubMed: Review of efficacy and safety data
- Manufacturer information for the Hettich EBA 200
- Product information for Vi PRP-PRO
Medical notice: This article presents published research findings and guideline positions for informational purposes. It does not contain a recommendation for or against a specific treatment and does not replace a medical examination, diagnosis or individual treatment decision. Product references relate exclusively to technical aspects of PRP preparation and not to a specific indication.